Globus Medical Inc (GMED) 24.61 $GMED
InsiderInsights.com Daily Round Up 3/20/15: DRRX, RWC, GEF.B, MRD
InsiderInsights - at Seeking Alpha - Sat Mar 21, 2:29AM CDT
NPBC: 10.80 (+0.18), HCOM: 26.13 (+0.08), DRII: 34.58 (+0.74), LGIH: 14.89 (+0.31), MRD: 17.70 (+0.02), STKL: 11.01 (+0.50), DRRX: 1.68 (-0.01), GOOG: 560.36 (+2.37), WSTC: 32.99 (+0.24), NLY: 10.74 (+0.04), PDVW: 48.29 (+3.29), GMED: 24.61 (-0.53), MHK: 181.03 (+1.16), NERV: 5.98 (-0.09), JAZZ: 189.01 (+1.89), RWC: 6.00 (-0.08), GOOGL: 564.95 (+1.28), ROST: 107.46 (+0.72)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Tue Mar 17, 6:56AM CDT
ELLI: 55.83 (+0.93), JCOM: 70.07 (+0.43), CAH: 91.25 (+1.33), CIEN: 20.63 (+0.16), AET: 108.63 (+0.32), ANAC: 54.24 (-1.88), CSL: 92.70 (+1.01), HSIC: 143.01 (+2.32), CAVM: 73.81 (+1.33), HAS: 61.08 (-0.02), MCHP: 50.87 (+0.57), COLM: 59.58 (+0.33), DEPO: 24.12 (-0.75), HRL: 56.80 (+0.81), COO: 187.44 (+0.08), DYAX: 17.00 (-0.45), LVLT: 55.40 (+0.73), CBRL: 155.21 (+0.37), AZO: 662.43 (-4.96), EQIX: 238.95 (+3.05), KNX: 34.50 (+0.39), HAE: 44.29 (-0.22), EL: 83.53 (+1.86), FSL: 43.39 (+0.82), CCK: 53.09 (+0.19), BLL: 71.20 (+0.63), CDW: 37.77 (+0.45), ADBE: 77.36 (+0.22), AFFX: 12.87 (-0.07), AGN: 240.22 (+2.88), DPS: 77.03 (+0.92), INFA: 44.57 (+0.72), APH: 60.05 (+0.08), GEVA: 111.92 (-5.44), LII: 109.77 (+0.31), GMED: 24.61 (-0.53), BJRI: 52.88 (-0.12), DPZ: 104.63 (+0.86), HBI: 34.18 (-0.16), FL: 62.70 (+0.62), DLX: 68.34 (+1.37), ABT: 47.47 (+0.03), KR: 76.83 (+0.43), ABCO: 52.92 (+0.41), DIOD: 30.23 (+0.49), LEG: 46.42 (+0.32), DIS: 108.43 (+1.06), GLW: 23.39 (+0.26), MAR: 84.04 (-0.27), LEA: 111.97 (+1.28), DISH: 73.41 (-0.97), IMAX: 34.54 (-0.02), CNC: 70.25 (-0.34), CTAS: 82.55 (-1.41), CMCSA: 59.45 (+0.71), FLO: 21.84 (+0.09), BIG: 50.14 (+0.10), CRM: 67.69 (-1.19)
LDR Holding: An Excellent Play In The Non-Fusion Spine Market
Andy Batts - at Seeking Alpha - Tue Mar 10, 6:45AM CDT
LDRH: 37.76 (+0.09), GMED: 24.61 (-0.53), NUVA: 45.60 (-1.07)
Globus Medical (GMED) Beats on Q4 Earnings, Sales in Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 8:40AM CST
Musculoskeletal implant manufacturer, Globus Medical Inc. (GMED), reported adjusted earnings per share ("EPS"
of 30 cents in the fourth quarter of 2014, beating the Zacks Consensus Estimate by 4 cents.
GMED: 24.61 (-0.53), ABAX: 65.61 (+1.33), LMNX: 15.98 (-0.08), AFFX: 12.87 (-0.07)
Globus Medical's (GMED) CEO David Paul on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 10:33PM CST
GMED: 24.61 (-0.53)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:35PM CST
CXO: 108.18 (+1.98), CSGP: 196.78 (-0.88), HK: 1.60 (+0.02), GPOR: 46.11 (+0.10), BLDP: 2.06 (-0.01), PRSS: 3.55 (-0.22), EAC: 4.63 (-0.71), GXP: 26.94 (+0.30), DXCM: 61.97 (-1.47), LHCG: 32.40 (-0.11), STAA: 7.39 (+0.05), ESRT: 18.96 (+0.42), PGTI: 11.24 (+0.14), ORIG: 6.29 (+0.30), CWT: 25.45 (+0.06), MCHX: 4.48 (+0.05), RGR: 50.51 (-0.18), CLUB: 6.23 (-0.08), MMLP: 34.71 (+0.95), AR: 36.03 (+0.40), IL: 11.62 (+0.05), FOE: 12.30 (+0.02), ARI: 17.67 (+0.53), ANIK: 40.84 (-0.63), FARO: 60.76 (unch), BWC: 30.41 (+0.68), ESV: 21.05 (+0.25), MELI: 124.59 (+1.68), EPAM: 61.38 (-0.20), OAS: 13.80 (-0.16), AWR: 41.40 (+0.45), BMRN: 125.17 (-2.32), SFM: 33.99 (+0.03), ELGX: 16.49 (+0.07), AEGN: 17.75 (+0.15), AREX: 6.48 (-0.26), MDVN: 135.56 (+1.09), AGO: 26.25 (+0.17), RIG: 14.99 (+0.83), GMED: 24.61 (-0.53), DRYS: 0.80 (+0.07), AMSG: 64.02 (-0.19), LGCY: 10.02 (-0.26), CHDN: 112.50 (+1.16), KW: 26.15 (+0.09), PVA: 7.64 (+0.05), PLKI: 59.94 (-0.46), RIGP: 13.59 (+0.45), LB: 93.40 (+0.30), CLVS: 78.26 (-3.17), SBY: 16.16 (+0.14), CEMP: 39.77 (-1.15), CHMT: 25.99 (+0.31), AVGO: 133.29 (+1.25), CRM: 67.69 (-1.19), EHTH: 10.24 (+0.06)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.10 (-0.04), AMRN: 2.52 (-0.03), HWAY: 21.46 (-0.09), HLS: 45.30 (+0.35), CYBX: 65.21 (-0.46), ESRX: 85.38 (+1.43), ECYT: 5.96 (-0.06), DXCM: 61.97 (-1.47), NSTG: 11.48 (-0.05), SRPT: 13.16 (-0.76), HZNP: 22.77 (-0.30), MDXG: 9.89 (-0.30), DEPO: 24.12 (-0.75), ANIK: 40.84 (-0.63), NKTR: 12.02 (+0.13), KERX: 14.31 (+0.68), ALIM: 5.12 (+0.08), EPZM: 19.91 (-0.88), AEGR: 27.20 (-0.20), MDRX: 12.05 (-0.06), ELGX: 16.49 (+0.07), NUVA: 45.60 (-1.07), HPTX: 40.49 (+0.85), GNMK: 13.82 (+0.36), MDVN: 135.56 (+1.09), HBIO: 5.40 (+0.13), ACAD: 34.45 (-0.54), ST: 57.45 (+0.54), RPTP: 11.86 (+0.14), FMI: 48.11 (-0.29), GMED: 24.61 (-0.53), JAZZ: 189.01 (+1.89), PTCT: 70.05 (+0.82), INFI: 15.39 (-1.14), ARNA: 4.80 (-0.21), EXEL: 2.82 (-0.02), NEO: 4.96 (+0.02), EXAS: 24.18 (-0.20), ALKS: 67.20 (-0.86), HTWR: 85.97 (-0.51), MNKD: 5.26 (-0.28), IPXL: 46.34 (-0.47), SQNM: 3.91 (-0.03), HALO: 14.63 (-1.43), ISIS: 73.59 (-3.49), CLVS: 78.26 (-3.17), BIO: 134.98 (-1.35), BIOS: 4.49 (-0.06), PCRX: 97.64 (-0.08)
Globus Medical Schedules Fourth Quarter and Full Year 2014 Earnings Release and Conference Call
Business Wire - Wed Feb 11, 4:02PM CST
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, will announce its financial results for the fourth quarter and year ended December 31, 2014 after the market close on Wednesday, February 25, 2015. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors.
GMED: 24.61 (-0.53)
U.S. Minimally Invasive Spinal Implant Market - 2015 Executive Summary
M2 - Fri Jan 09, 8:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/lkvb2c/u_s_minimally) has announced the addition of the "U.S. Minimally Invasive Spinal Implant Market - 2015 (Executive Summary)" report to their offering. Growth in the minimally invasive spinal implant market is largely driven by the advantages of minimally invasive surgery over open surgery; these include reduced trauma, shorter hospital stays, lower post-operative medication use and earlier return to work. However, growth is expected to slow over the forecast period as a result of the increasing penetration of MIS procedures into the traditional fusion market and increases in the competing motion preservation market. The vast majority of patients, when given the option, will choose minimally invasive procedures rather than traditional open fusion surgeries. Patients are drawn to the advantages of less invasive techniques. MIS reduces muscle and tissue damage at the surgical site, decreases complications and limits intraoperative time. Clinical outcomes have been largely positive, further favoring the use of MIS techniques over open procedures. From a practice standpoint, more surgeons are looking into MIS approaches to not only market their practice competitively, but also to increase their potential revenues. MIS procedures often require less intraoperative and hospital time for the patient. As a result, surgeons would theoretically be able to perform more procedures within the same allotted amount of time than if they were to perform the procedures via an open approach. Key Topics Covered: - U.S. Minimally Invasive Spinal Implant Market - Spinous Process Fixation Market - Facet Fixation Market - Mis Interbody Fusion Market - Mis Pedicle Screw Market - Mis Sacroiliac Joint Fusion Market - Leading Competitors Companies Mentioned - Alphatec Spine - Amedica - Baxano Surgical - Biomet - DePuy Synthes - Globus Medical - Interventional Spine - K2M - Medtronic - NuVasive - Nutech - Orthofix - OsteoMed - Pioneer Surgical - SI-BONE - Stryker - VG Innovations - Zimmer - Zyga Technology For more information visit http://www.researchandmarkets.com/research/lk..._minimally
MDT: 78.02 (+0.36), GMED: 24.61 (-0.53)
Spinal Products Firm NuVasive Ripe For Expansion
at Investor's Business Daily - Thu Jan 08, 2:17PM CST
Shares of NuVasive (NUVA) moved higher in early trading on the stock market today after the maker of spinal products received an analyst upgrade that cited its potential to grab more market share, particularly internationally. In a morning research...
LDRH: 37.76 (+0.09), MDT: 78.02 (+0.36), GMED: 24.61 (-0.53), BAX: 68.18 (+0.20), COV: 106.71 (-1.36), EW: 146.77 (-2.17), NUVA: 45.60 (-1.07)
2015 U.S. Minimally Invasive Spinal Implant Market Report
M2 - Thu Jan 08, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/dp4wpm/u_s_minimally) has announced the addition of the "U.S. Minimally Invasive Spinal Implant Market - 2015" report to their offering. The U.S. market for minimally invasive surgery (MIS) spinal implants includes spinous process fixation, facet fixation, MIS interbody fusion, MIS pedicle screws and MIS sacroiliac joint fusion. This U.S. Minimally Invasive Spinal Implant Market report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Growth in the minimally invasive spinal implant market is largely driven by the advantages of minimally invasive surgery over open surgery; these include reduced trauma, shorter hospital stays, lower post-operative medication use and earlier return to work. However, growth is expected to slow over the forecast period as a result of the increasing penetration of MIS procedures into the traditional fusion market and increases in the competing motion preservation market. The vast majority of patients, when given the option, will choose minimally invasive procedures rather than traditional open fusion surgeries. Patients are drawn to the advantages of less invasive techniques. MIS reduces muscle and tissue damage at the surgical site, decreases complications and limits intraoperative time. Clinical outcomes have been largely positive, further favoring the use of MIS techniques over open procedures. From a practice standpoint, more surgeons are looking into MIS approaches to not only market their practice competitively, but also to increase their potential revenues. MIS procedures often require less intraoperative and hospital time for the patient. As a result, surgeons would theoretically be able to perform more procedures within the same allotted amount of time than if they were to perform the procedures via an open approach. Report Highlights: - Discusses changes to reimbursement policies among healthcare insurers will drastically change the market landscape - Recent introduction of spinous process fixation devices - Recent policy changes effecting the spinous process fixation market - Emerging technology in the minimally invasive surgery field - Pricing pressures driven by hospitals and insurance providers will effect the MIS Interbody Fusion Market - MIS Sacroiliac Joint Fusion Market change to a category I CPT code Companies Mentioned - Alphatec Spine - Amedica - Baxano Surgical - Biomet - DePuy Synthes - Globus Medical - Interventional Spine - K2M - Medtronic - NuVasive - Nutech - Orthofix - OsteoMed - Pioneer Surgical - SI-BONE - Stryker - VG Innovations - Zimmer - Zyga Technology For more information visit http://www.researchandmarkets.com/research/dp..._minimally
MDT: 78.02 (+0.36), GMED: 24.61 (-0.53)
Globus Medical Announces Preliminary Q4 & 2014 Sales Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 4:35PM CST
Musculoskeletal implant manufacturer, Globus Medical Inc. (GMED) recently announced preliminary sales result for the fourth quarter and full-year 2014
ABMD: 60.00 (-1.10), GMED: 24.61 (-0.53), ANGO: 18.65 (+0.12), SURG: 5.21 (-0.02)
Globus Med sees Q4 sales up over 9%
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 3:19PM CST
GMED: 24.61 (-0.53)
Globus Medical Reports Preliminary Fourth Quarter and Full Year Sales Results
Business Wire - Tue Jan 06, 3:05PM CST
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced preliminary unaudited sales results for the year ending December 31, 2014, in advance of its annual national sales meeting being held later this week. The company anticipates fourth quarter 2014 sales of approximately $128.5 million, an 11.5% increase over fourth quarter 2013. Full year 2014 estimated sales increased to approximately $474 million or 9.1% over the prior year, exceeding the company's previous guidance range of $462-467 million.
GMED: 24.61 (-0.53)
Zynerba Pharmaceuticals Appoints Richard A. Baron VP and CFO
PR Newswire - Mon Jan 05, 6:30AM CST
Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, announced that the appointment of Richard A. Baron as vice president and chief financial officer (CFO) effective today. Mr. Baron offers more than 30 years of experience in executive finance leadership for early-stage, pharmaceutical and healthcare companies.
JNJ: 102.40 (+0.71), GMED: 24.61 (-0.53), LLY: 76.12 (+1.90)
Fluidigm (FLDM) Upgraded to Strong Buy on Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:40AM CST
On Dec 27, 2014, Zacks Investment Research upgraded Fluidigm Corporation (FLDM) to a Zacks Rank #1 (Strong Buy).
FLDM: 45.47 (-0.07), GMED: 24.61 (-0.53), INGN: 32.05 (-0.10), LMNX: 15.98 (-0.08)
Masimo's Multigas Monitoring Module Gets 510(k), CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:55PM CST
Masimo Corporation's (MASI) ISA OR+ multigas monitoring is a Masimo Open Connect (MOC-9) Module for the Root patient monitoring and connectivity platform.
MASI: 31.01 (-0.55), GMED: 24.61 (-0.53), COV: 106.71 (-1.36), EW: 146.77 (-2.17)
North America Spinal Surgery Market - Industry Analysis And Market Forecast 2014-2020
M2 - Tue Dec 09, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w58zvn/north_america) has announced the addition of the "North America Spinal Surgery Market - Industry Analysis And Market Forecast 2014-2020" report to their offering. The North American market for Spinal Surgery is estimated to be valued as $7.76 billion for the year 2014 and is expected to reach $11.28 billion by the end of 2020. The CAGR during this period of forecast is 6.43%. Spinal surgical device market is a very significant and money-spinning sub section of orthopedic industry. Spine surgery is traditionally done as "open surgery," wherein a long incision allows the surgeon to access the spine anatomy. In the recent years, a minimally invasive surgical device technique has received increasing attention as it does not involve a long incision and hence causes minimal damage to the muscles around the spine. This results in lesser post-operative pain and faster recovery. Spinal surgeries can be classified as: - ALIF (Anterior Lumbar Interbody Fusion): for removal of a complete intervertebral disc. - Anterior Cervical Discectomy: to remove selected discs. - Bone Grafting: to place bone into an area of the spine in order to get solid bone healing (spinal fusion). - Discectomy: to remove a part or all of an intervertebral disc from the spine. - Spinal Decompression - Spinal Fusion - Spinal Instrumentation - Spinal Osteotomy - Thoracoscopic Release - TLIF The major players in this market are Globus Medical, Zimmer Holdings, Medtronic, Paradigm Spine, Stryker Corporation and Aplhatec Holdings. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. North American Spinal Surgery Market Segmentation 5. Competitive Landscape 6. Company Profiles For more information visit http://www.researchandmarkets.com/research/w5...th_america
ZMH: 118.76 (+0.20), MDT: 78.02 (+0.36), GMED: 24.61 (-0.53), SYK: 93.65 (+0.08)
Globus Medical: Best Positioned Play In The Spine Recovery Market
Value Wagon - at Seeking Alpha - Thu Nov 20, 8:26AM CST
GMED: 24.61 (-0.53)
InsiderInsights.com Daily Round Up 3/20/15: DRRX, RWC, GEF.B, MRD
InsiderInsights - at Seeking Alpha - Sat Mar 21, 2:29AM CDT
NPBC: 10.80 (+0.18), HCOM: 26.13 (+0.08), DRII: 34.58 (+0.74), LGIH: 14.89 (+0.31), MRD: 17.70 (+0.02), STKL: 11.01 (+0.50), DRRX: 1.68 (-0.01), GOOG: 560.36 (+2.37), WSTC: 32.99 (+0.24), NLY: 10.74 (+0.04), PDVW: 48.29 (+3.29), GMED: 24.61 (-0.53), MHK: 181.03 (+1.16), NERV: 5.98 (-0.09), JAZZ: 189.01 (+1.89), RWC: 6.00 (-0.08), GOOGL: 564.95 (+1.28), ROST: 107.46 (+0.72)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Tue Mar 17, 6:56AM CDT
ELLI: 55.83 (+0.93), JCOM: 70.07 (+0.43), CAH: 91.25 (+1.33), CIEN: 20.63 (+0.16), AET: 108.63 (+0.32), ANAC: 54.24 (-1.88), CSL: 92.70 (+1.01), HSIC: 143.01 (+2.32), CAVM: 73.81 (+1.33), HAS: 61.08 (-0.02), MCHP: 50.87 (+0.57), COLM: 59.58 (+0.33), DEPO: 24.12 (-0.75), HRL: 56.80 (+0.81), COO: 187.44 (+0.08), DYAX: 17.00 (-0.45), LVLT: 55.40 (+0.73), CBRL: 155.21 (+0.37), AZO: 662.43 (-4.96), EQIX: 238.95 (+3.05), KNX: 34.50 (+0.39), HAE: 44.29 (-0.22), EL: 83.53 (+1.86), FSL: 43.39 (+0.82), CCK: 53.09 (+0.19), BLL: 71.20 (+0.63), CDW: 37.77 (+0.45), ADBE: 77.36 (+0.22), AFFX: 12.87 (-0.07), AGN: 240.22 (+2.88), DPS: 77.03 (+0.92), INFA: 44.57 (+0.72), APH: 60.05 (+0.08), GEVA: 111.92 (-5.44), LII: 109.77 (+0.31), GMED: 24.61 (-0.53), BJRI: 52.88 (-0.12), DPZ: 104.63 (+0.86), HBI: 34.18 (-0.16), FL: 62.70 (+0.62), DLX: 68.34 (+1.37), ABT: 47.47 (+0.03), KR: 76.83 (+0.43), ABCO: 52.92 (+0.41), DIOD: 30.23 (+0.49), LEG: 46.42 (+0.32), DIS: 108.43 (+1.06), GLW: 23.39 (+0.26), MAR: 84.04 (-0.27), LEA: 111.97 (+1.28), DISH: 73.41 (-0.97), IMAX: 34.54 (-0.02), CNC: 70.25 (-0.34), CTAS: 82.55 (-1.41), CMCSA: 59.45 (+0.71), FLO: 21.84 (+0.09), BIG: 50.14 (+0.10), CRM: 67.69 (-1.19)
LDR Holding: An Excellent Play In The Non-Fusion Spine Market
Andy Batts - at Seeking Alpha - Tue Mar 10, 6:45AM CDT
LDRH: 37.76 (+0.09), GMED: 24.61 (-0.53), NUVA: 45.60 (-1.07)
Globus Medical (GMED) Beats on Q4 Earnings, Sales in Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 8:40AM CST
Musculoskeletal implant manufacturer, Globus Medical Inc. (GMED), reported adjusted earnings per share ("EPS"
of 30 cents in the fourth quarter of 2014, beating the Zacks Consensus Estimate by 4 cents. GMED: 24.61 (-0.53), ABAX: 65.61 (+1.33), LMNX: 15.98 (-0.08), AFFX: 12.87 (-0.07)
Globus Medical's (GMED) CEO David Paul on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 10:33PM CST
GMED: 24.61 (-0.53)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:35PM CST
CXO: 108.18 (+1.98), CSGP: 196.78 (-0.88), HK: 1.60 (+0.02), GPOR: 46.11 (+0.10), BLDP: 2.06 (-0.01), PRSS: 3.55 (-0.22), EAC: 4.63 (-0.71), GXP: 26.94 (+0.30), DXCM: 61.97 (-1.47), LHCG: 32.40 (-0.11), STAA: 7.39 (+0.05), ESRT: 18.96 (+0.42), PGTI: 11.24 (+0.14), ORIG: 6.29 (+0.30), CWT: 25.45 (+0.06), MCHX: 4.48 (+0.05), RGR: 50.51 (-0.18), CLUB: 6.23 (-0.08), MMLP: 34.71 (+0.95), AR: 36.03 (+0.40), IL: 11.62 (+0.05), FOE: 12.30 (+0.02), ARI: 17.67 (+0.53), ANIK: 40.84 (-0.63), FARO: 60.76 (unch), BWC: 30.41 (+0.68), ESV: 21.05 (+0.25), MELI: 124.59 (+1.68), EPAM: 61.38 (-0.20), OAS: 13.80 (-0.16), AWR: 41.40 (+0.45), BMRN: 125.17 (-2.32), SFM: 33.99 (+0.03), ELGX: 16.49 (+0.07), AEGN: 17.75 (+0.15), AREX: 6.48 (-0.26), MDVN: 135.56 (+1.09), AGO: 26.25 (+0.17), RIG: 14.99 (+0.83), GMED: 24.61 (-0.53), DRYS: 0.80 (+0.07), AMSG: 64.02 (-0.19), LGCY: 10.02 (-0.26), CHDN: 112.50 (+1.16), KW: 26.15 (+0.09), PVA: 7.64 (+0.05), PLKI: 59.94 (-0.46), RIGP: 13.59 (+0.45), LB: 93.40 (+0.30), CLVS: 78.26 (-3.17), SBY: 16.16 (+0.14), CEMP: 39.77 (-1.15), CHMT: 25.99 (+0.31), AVGO: 133.29 (+1.25), CRM: 67.69 (-1.19), EHTH: 10.24 (+0.06)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.10 (-0.04), AMRN: 2.52 (-0.03), HWAY: 21.46 (-0.09), HLS: 45.30 (+0.35), CYBX: 65.21 (-0.46), ESRX: 85.38 (+1.43), ECYT: 5.96 (-0.06), DXCM: 61.97 (-1.47), NSTG: 11.48 (-0.05), SRPT: 13.16 (-0.76), HZNP: 22.77 (-0.30), MDXG: 9.89 (-0.30), DEPO: 24.12 (-0.75), ANIK: 40.84 (-0.63), NKTR: 12.02 (+0.13), KERX: 14.31 (+0.68), ALIM: 5.12 (+0.08), EPZM: 19.91 (-0.88), AEGR: 27.20 (-0.20), MDRX: 12.05 (-0.06), ELGX: 16.49 (+0.07), NUVA: 45.60 (-1.07), HPTX: 40.49 (+0.85), GNMK: 13.82 (+0.36), MDVN: 135.56 (+1.09), HBIO: 5.40 (+0.13), ACAD: 34.45 (-0.54), ST: 57.45 (+0.54), RPTP: 11.86 (+0.14), FMI: 48.11 (-0.29), GMED: 24.61 (-0.53), JAZZ: 189.01 (+1.89), PTCT: 70.05 (+0.82), INFI: 15.39 (-1.14), ARNA: 4.80 (-0.21), EXEL: 2.82 (-0.02), NEO: 4.96 (+0.02), EXAS: 24.18 (-0.20), ALKS: 67.20 (-0.86), HTWR: 85.97 (-0.51), MNKD: 5.26 (-0.28), IPXL: 46.34 (-0.47), SQNM: 3.91 (-0.03), HALO: 14.63 (-1.43), ISIS: 73.59 (-3.49), CLVS: 78.26 (-3.17), BIO: 134.98 (-1.35), BIOS: 4.49 (-0.06), PCRX: 97.64 (-0.08)
Globus Medical Schedules Fourth Quarter and Full Year 2014 Earnings Release and Conference Call
Business Wire - Wed Feb 11, 4:02PM CST
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, will announce its financial results for the fourth quarter and year ended December 31, 2014 after the market close on Wednesday, February 25, 2015. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors.
GMED: 24.61 (-0.53)
U.S. Minimally Invasive Spinal Implant Market - 2015 Executive Summary
M2 - Fri Jan 09, 8:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/lkvb2c/u_s_minimally) has announced the addition of the "U.S. Minimally Invasive Spinal Implant Market - 2015 (Executive Summary)" report to their offering. Growth in the minimally invasive spinal implant market is largely driven by the advantages of minimally invasive surgery over open surgery; these include reduced trauma, shorter hospital stays, lower post-operative medication use and earlier return to work. However, growth is expected to slow over the forecast period as a result of the increasing penetration of MIS procedures into the traditional fusion market and increases in the competing motion preservation market. The vast majority of patients, when given the option, will choose minimally invasive procedures rather than traditional open fusion surgeries. Patients are drawn to the advantages of less invasive techniques. MIS reduces muscle and tissue damage at the surgical site, decreases complications and limits intraoperative time. Clinical outcomes have been largely positive, further favoring the use of MIS techniques over open procedures. From a practice standpoint, more surgeons are looking into MIS approaches to not only market their practice competitively, but also to increase their potential revenues. MIS procedures often require less intraoperative and hospital time for the patient. As a result, surgeons would theoretically be able to perform more procedures within the same allotted amount of time than if they were to perform the procedures via an open approach. Key Topics Covered: - U.S. Minimally Invasive Spinal Implant Market - Spinous Process Fixation Market - Facet Fixation Market - Mis Interbody Fusion Market - Mis Pedicle Screw Market - Mis Sacroiliac Joint Fusion Market - Leading Competitors Companies Mentioned - Alphatec Spine - Amedica - Baxano Surgical - Biomet - DePuy Synthes - Globus Medical - Interventional Spine - K2M - Medtronic - NuVasive - Nutech - Orthofix - OsteoMed - Pioneer Surgical - SI-BONE - Stryker - VG Innovations - Zimmer - Zyga Technology For more information visit http://www.researchandmarkets.com/research/lk..._minimally
MDT: 78.02 (+0.36), GMED: 24.61 (-0.53)
Spinal Products Firm NuVasive Ripe For Expansion
at Investor's Business Daily - Thu Jan 08, 2:17PM CST
Shares of NuVasive (NUVA) moved higher in early trading on the stock market today after the maker of spinal products received an analyst upgrade that cited its potential to grab more market share, particularly internationally. In a morning research...
LDRH: 37.76 (+0.09), MDT: 78.02 (+0.36), GMED: 24.61 (-0.53), BAX: 68.18 (+0.20), COV: 106.71 (-1.36), EW: 146.77 (-2.17), NUVA: 45.60 (-1.07)
2015 U.S. Minimally Invasive Spinal Implant Market Report
M2 - Thu Jan 08, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/dp4wpm/u_s_minimally) has announced the addition of the "U.S. Minimally Invasive Spinal Implant Market - 2015" report to their offering. The U.S. market for minimally invasive surgery (MIS) spinal implants includes spinous process fixation, facet fixation, MIS interbody fusion, MIS pedicle screws and MIS sacroiliac joint fusion. This U.S. Minimally Invasive Spinal Implant Market report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Growth in the minimally invasive spinal implant market is largely driven by the advantages of minimally invasive surgery over open surgery; these include reduced trauma, shorter hospital stays, lower post-operative medication use and earlier return to work. However, growth is expected to slow over the forecast period as a result of the increasing penetration of MIS procedures into the traditional fusion market and increases in the competing motion preservation market. The vast majority of patients, when given the option, will choose minimally invasive procedures rather than traditional open fusion surgeries. Patients are drawn to the advantages of less invasive techniques. MIS reduces muscle and tissue damage at the surgical site, decreases complications and limits intraoperative time. Clinical outcomes have been largely positive, further favoring the use of MIS techniques over open procedures. From a practice standpoint, more surgeons are looking into MIS approaches to not only market their practice competitively, but also to increase their potential revenues. MIS procedures often require less intraoperative and hospital time for the patient. As a result, surgeons would theoretically be able to perform more procedures within the same allotted amount of time than if they were to perform the procedures via an open approach. Report Highlights: - Discusses changes to reimbursement policies among healthcare insurers will drastically change the market landscape - Recent introduction of spinous process fixation devices - Recent policy changes effecting the spinous process fixation market - Emerging technology in the minimally invasive surgery field - Pricing pressures driven by hospitals and insurance providers will effect the MIS Interbody Fusion Market - MIS Sacroiliac Joint Fusion Market change to a category I CPT code Companies Mentioned - Alphatec Spine - Amedica - Baxano Surgical - Biomet - DePuy Synthes - Globus Medical - Interventional Spine - K2M - Medtronic - NuVasive - Nutech - Orthofix - OsteoMed - Pioneer Surgical - SI-BONE - Stryker - VG Innovations - Zimmer - Zyga Technology For more information visit http://www.researchandmarkets.com/research/dp..._minimally
MDT: 78.02 (+0.36), GMED: 24.61 (-0.53)
Globus Medical Announces Preliminary Q4 & 2014 Sales Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 4:35PM CST
Musculoskeletal implant manufacturer, Globus Medical Inc. (GMED) recently announced preliminary sales result for the fourth quarter and full-year 2014
ABMD: 60.00 (-1.10), GMED: 24.61 (-0.53), ANGO: 18.65 (+0.12), SURG: 5.21 (-0.02)
Globus Med sees Q4 sales up over 9%
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 3:19PM CST
GMED: 24.61 (-0.53)
Globus Medical Reports Preliminary Fourth Quarter and Full Year Sales Results
Business Wire - Tue Jan 06, 3:05PM CST
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced preliminary unaudited sales results for the year ending December 31, 2014, in advance of its annual national sales meeting being held later this week. The company anticipates fourth quarter 2014 sales of approximately $128.5 million, an 11.5% increase over fourth quarter 2013. Full year 2014 estimated sales increased to approximately $474 million or 9.1% over the prior year, exceeding the company's previous guidance range of $462-467 million.
GMED: 24.61 (-0.53)
Zynerba Pharmaceuticals Appoints Richard A. Baron VP and CFO
PR Newswire - Mon Jan 05, 6:30AM CST
Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, announced that the appointment of Richard A. Baron as vice president and chief financial officer (CFO) effective today. Mr. Baron offers more than 30 years of experience in executive finance leadership for early-stage, pharmaceutical and healthcare companies.
JNJ: 102.40 (+0.71), GMED: 24.61 (-0.53), LLY: 76.12 (+1.90)
Fluidigm (FLDM) Upgraded to Strong Buy on Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:40AM CST
On Dec 27, 2014, Zacks Investment Research upgraded Fluidigm Corporation (FLDM) to a Zacks Rank #1 (Strong Buy).
FLDM: 45.47 (-0.07), GMED: 24.61 (-0.53), INGN: 32.05 (-0.10), LMNX: 15.98 (-0.08)
Masimo's Multigas Monitoring Module Gets 510(k), CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:55PM CST
Masimo Corporation's (MASI) ISA OR+ multigas monitoring is a Masimo Open Connect (MOC-9) Module for the Root patient monitoring and connectivity platform.
MASI: 31.01 (-0.55), GMED: 24.61 (-0.53), COV: 106.71 (-1.36), EW: 146.77 (-2.17)
North America Spinal Surgery Market - Industry Analysis And Market Forecast 2014-2020
M2 - Tue Dec 09, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w58zvn/north_america) has announced the addition of the "North America Spinal Surgery Market - Industry Analysis And Market Forecast 2014-2020" report to their offering. The North American market for Spinal Surgery is estimated to be valued as $7.76 billion for the year 2014 and is expected to reach $11.28 billion by the end of 2020. The CAGR during this period of forecast is 6.43%. Spinal surgical device market is a very significant and money-spinning sub section of orthopedic industry. Spine surgery is traditionally done as "open surgery," wherein a long incision allows the surgeon to access the spine anatomy. In the recent years, a minimally invasive surgical device technique has received increasing attention as it does not involve a long incision and hence causes minimal damage to the muscles around the spine. This results in lesser post-operative pain and faster recovery. Spinal surgeries can be classified as: - ALIF (Anterior Lumbar Interbody Fusion): for removal of a complete intervertebral disc. - Anterior Cervical Discectomy: to remove selected discs. - Bone Grafting: to place bone into an area of the spine in order to get solid bone healing (spinal fusion). - Discectomy: to remove a part or all of an intervertebral disc from the spine. - Spinal Decompression - Spinal Fusion - Spinal Instrumentation - Spinal Osteotomy - Thoracoscopic Release - TLIF The major players in this market are Globus Medical, Zimmer Holdings, Medtronic, Paradigm Spine, Stryker Corporation and Aplhatec Holdings. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. North American Spinal Surgery Market Segmentation 5. Competitive Landscape 6. Company Profiles For more information visit http://www.researchandmarkets.com/research/w5...th_america
ZMH: 118.76 (+0.20), MDT: 78.02 (+0.36), GMED: 24.61 (-0.53), SYK: 93.65 (+0.08)
Globus Medical: Best Positioned Play In The Spine Recovery Market
Value Wagon - at Seeking Alpha - Thu Nov 20, 8:26AM CST
GMED: 24.61 (-0.53)
